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Association of Obstructive Sleep Apnea With Cardiovascular
Outcomes in Patients With Acute Coronary Syndrome
Jingyao Fan, MD;* Xiao Wang, MD;* Xinliang Ma, MD, PhD; Virend K. Somers, MD, PhD; Shaoping Nie, MD, PhD; Yongxiang Wei, MD, PhD
Background-—The prognostic signiﬁcance of obstructive sleep apnea (OSA) in patients with acute coronary syndrome (ACS) in the
contemporary era is unclear. We performed a large, prospective cohort study and did a landmark analysis to delineate the
association of OSA with subsequent cardiovascular events after ACS onset.
Methods and Results-—Between June 2015 and May 2017, consecutive eligible patients admitted for ACS underwent
cardiorespiratory polygraphy during hospitalization. OSA was deﬁned as an apnea-hypopnea index ≥15 eventsh1. The primary
end point was major adverse cardiovascular and cerebrovascular event (MACCE), including cardiovascular death, myocardial
infarction, stroke, ischemia-driven revascularization, or hospitalization for unstable angina or heart failure. OSA was present in 403
of 804 (50.1%) patients. During median follow-up of 1 year, cumulative incidence of MACCE was signiﬁcantly higher in the OSA
group than in the non-OSA group (log-rank, P=0.041). Multivariate analysis showed that OSA was nominally associated with
incidence of MACCE (adjusted hazard ratio, 1.55; 95% CI, 0.94–2.57; P=0.085). In the landmark analysis, patients with OSA had
3.9 times the risk of incurring a MACCE after 1 year (adjusted hazard ratio, 3.87; 95% CI, 1.20–12.46; P=0.023), but no increased
risk was found within 1-year follow-up (adjusted hazard ratio, 1.18; 95% CI, 0.67–2.09; P=0.575). No signiﬁcant differences were
found in the incidence of cardiovascular death, myocardial infarction, and ischemia-driven revascularization, except for a higher
rate of hospitalization for unstable angina in the OSA group than in the non-OSA group (adjusted hazard ratio, 2.10; 95% CI, 1.09–
4.05; P=0.027).
Conclusions-—There was no independent correlation between OSA and 1-year MACCE after ACS. The increased risk associated
with OSA was only observed after 1-year follow-up. Efﬁcacy of OSA treatment as secondary prevention after ACS requires further
investigation. ( J Am Heart Assoc. 2019;8:e010826. DOI: 10.1161/JAHA.118.010826.)
Key Words: acute coronary syndrome • obstructive sleep apnea • outcome
O bstructive sleep apnea (OSA) is highly prevalent inpatients with cardiovascular diseases.1,2 Increasing
evidence indicates that OSA is associated with incidence
and progression of coronary artery disease3–5 and
cerebrovascular disease.6 Among patients with coronary
artery disease, those with acute coronary syndrome (ACS)
represent a high-risk subset and generally have higher
mortality than patients with stable angina.7 Compared with
the general population, prevalence of OSA is higher in ACS
patients and ranges from 36% to 63% across various
ethnicities.8 Previous observational studies have examined
whether OSA signiﬁcantly increased risk of recurrent
cardiovascular events in patients with ACS and/or under-
going percutaneous coronary intervention (PCI).9–12 How-
ever, results are inconsistent, and most studies, except the
Sleep and Stent study,12 were not done in the era of new-
generation drug-eluting stents and modern antithrombotic
therapy, thus precluding deﬁnite conclusions in the context
of contemporary therapeutic strategies. Given that guide-
line-based optimal medical therapy was administered after
ACS onset, especially within the ﬁrst year,13,14 we hypoth-
esized that the prognostic signiﬁcance of OSA would vary
across different time periods after ACS presentation.
Therefore, we performed a large-scale, prospective cohort
study and did a landmark analysis to delineate the
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association of OSA with subsequent cardiovascular out-
comes in patients with ACS.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Design and Population
The OSA-ACS project (NCT03362385) is a large-scale, single-
center, prospective, observational study to assess the associ-
ation of OSAwith cardiovascular outcomes of patients with ACS
in the contemporary era. For the current study, we performed a
landmark analysis at a median follow-up of 1 year. Consecutive
patients aged 18 to 85 years and admitted for ACS to the
Emergency & Critical Care Center of Beijing Anzhen Hospital,
Capital Medical University between June 2015 and May 2017
were eligible for inclusion. ACS was deﬁned as acute presen-
tation of coronary disease, including ST-segment elevation
myocardial infarction, non-ST-segment elevation myocardial
infarction, and unstable angina. Exclusion criteria were as
follows: cardiogenic shock, cardiac arrest, previous or current
use of continuous positive airway pressure (CPAP), malignancy,
and failed sleep study (patients without adequate and satisfac-
tory signal recording). Patients with predominantly central
sleep apnea (≥50% central events or central apnea hypopnea
index [AHI] ≥10h1) and those receiving regular CPAP therapy
(>3 months) after hospitalization were excluded from the
analysis. This study conformed to the STROBE (Strengthening
the Reporting of Observational studies in Epidemiology)
guidelines and was conducted in accord with the Declaration
of Helsinki. The Ethics Committee of Beijing Anzhen Hospital,
Capital Medical University approved the study (2013025). All
patients provided informed consent.
Overnight Sleep Study
All patients underwent an overnight sleep study after clinical
stabilization during hospitalization (within 2 weeks after
admission) using portable cardiorespiratory polygraphy
(ApneaLink, Resmed, Australia), which was validated in the
SAVE (Sleep Apnea Cardiovascular Endpoints) study.15,16
Nasal airﬂow, thoracoabdominal movements, arterial oxygen
saturation, and snoring episodes were recorded. An apnea
was deﬁned by an absence of airﬂow lasting ≥10 seconds
(obstructive if thoracoabdominal movement was present and
central if thoracoabdominal movement was absent). Hypop-
nea was deﬁned as a reduction in airﬂow of >30% for
≥10 seconds and associated with a decrease in arterial
oxygen saturation >4%. AHI was deﬁned as the number of
apneas and hypopneas per hour of total recording time.
Recruited patients were categorized into OSA (AHI
≥15 eventsh1) and non-OSA (AHI <15 eventsh1) groups.
A minimum of 3 hours of satisfactory polygraphy signal
recording was considered as a valid test. All studies were
double scored manually by independent sleep technologists
(J.F., X.W.). Further scoring was performed in cases of
discrepancy by a senior consultant in sleep medicine (Y.W.).
Procedures and Management
All patients received standard care during index ACS hospi-
talization according to current guidelines.13,14 PCI with
stenting or coronary artery bypass grafting was performed if
clinically indicated. At discharge, all patients were prescribed
aspirin (100 mg per day) and clopidogrel (75 mg per day) or
ticagrelor (90 mg twice a day) for at least 1 year unless there
were contraindications. For patients with moderate-to-severe
sleep apnea (AHI ≥15), particularly those with excessive
daytime sleepiness, we referred them to a sleep center for
further evaluation and consideration of CPAP therapy.
Clinical Perspective
What Is New?
• There was no independent correlation between obstructive
sleep apnea (OSA) and 1-year major adverse cardiovascular
and cerebrovascular event after acute coronary syndrome.
• Patients with OSA had 3.9 times the risk of incurring a
major adverse cardiovascular and cerebrovascular event
after 1 year, but no increased risk was evident within
1 year.
• No signiﬁcant differences were found in the incidence of
cardiovascular death, myocardial infarction, and ischemia-
driven revascularization, except for a higher rate of hospi-
talization for unstable angina in the OSA group than in the
non-OSA group.
What Are the Clinical Implications?
• The adverse effect of OSA in acute coronary syndrome
patients might become more pronounced with an increasing
duration of follow-up.
• Treatment effects of continuous positive airway pressure for
secondary prevention of acute coronary syndrome still need
to be evaluated.
• Appropriate timing and duration of intervention warrants
further investigation, given that any randomized trial of
continuous positive airway pressure or other therapy for
≤1 year will be unlikely to demonstrate signiﬁcant beneﬁt of
therapy, given the absence of signiﬁcant risk associated
with OSA within the ﬁrst year of acute coronary syndrome.
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Follow-up and Outcomes
Follow-up started at the time of the sleep study and was
performed at 1 month, 3 months, 6 months, 1 year, and then
every 6 months thereafter (at least 3 months and up to
2 years). Clinical events were collected by clinic visit, medical
chart review, or telephone calls by an investigator who was
blinded to patients’ sleep results. All clinical events were
conﬁrmed by source documentation and were adjudicated by
the clinical event committee.
The primary end point was major adverse cardiovascular
and cerebrovascular event (MACCE), deﬁned as a composite
of cardiovascular death, myocardial infarction (MI), stroke,
ischemia-driven revascularization, or hospitalization for unsta-
ble angina or heart failure. Secondary end points included
components of primary end point, all-cause death, all repeat
revascularization, and a composite of all events. All end points
were deﬁned in accord with the proposed deﬁnitions by the
Standardized Data Collection for Cardiovascular Trials
Initiative.17 Brieﬂy, cardiovascular death was deﬁned as death
related to proximate cardiovascular causes, procedure-related
complications, or any death unless an unequivocal noncar-
diovascular cause could be established. MI was deﬁned as
recurrence of spontaneous ST-segment elevation myocardial
infarction or non-ST-segment elevation myocardial infarction.
Stroke included ischemic stroke and hemorrhagic stroke,
which were veriﬁed by neurologists. Ischemia-driven revascu-
larization was deﬁned as any repeat PCI or coronary artery
bypass grafting performed for either: MI, unstable angina,
stable angina, or documented silent ischemia. Repeat revas-
cularization was further classiﬁed into target vessel or non-
target-vessel revascularization as well as PCI or coronary
artery bypass grafting.
Statistical Analyses
Continuous variables are shown as meanSD or median (ﬁrst
and third quartiles) and were compared by using the Student t
test or Mann–Whitney U test. Categorical variables are
presented as the number (percentage) and were compared
using v2 statistics or Fisher’s exact test, as appropriate.
Time-to-event data were summarized as Kaplan–Meier
estimates and were compared by the log-rank test. Multivari-
able Cox regression analyses were performed to determine
independent predictors of MACCE and other cardiovascular
events, and the adjusted hazard ratio (HR) with 95% CI were
calculated. Baseline variables that were considered clinically
relevant or that showed a univariate relationship with
outcome were entered into the Cox regression models.
Variables for inclusion were carefully chosen, given the
number of events available, to ensure parsimony of the ﬁnal
models. If the patient experienced more than 1 event during
the follow-up period, only the ﬁrst event was included in the
analysis. Landmark analyses were performed according to a
cut-off point of 1 year after sleep study, with HRs calculated
separately for events that occurred within 1 year and those
that occurred after 1 year.
All statistical analyses were conducted with SPSS (version
22.0[ IBM SPSS Inc, Armonk, NY) and Stata software (version
11.2; StataCorp LP, College Station, TX). A 2-sided P<0.05
was considered statistically signiﬁcant.
Results
Baseline Characteristics
In total, 899 consecutive eligible patients with ACS were
prospectively enrolled, of whom 867 underwent a successful
overnight sleep study. After exclusion of patients according to
predeﬁned criteria, 804 patients were included in the ﬁnal
analysis (Figure 1). Mean patient age was 57.510.2 years,
and 82.6% were male. Patients with OSA had higher body
mass index (P<0.001) and waist-to-hip ratio (P<0.001).
Medical history was comparable between OSA and non-OSA
groups, except previous PCI or coronary artery bypass
grafting, which was more frequent in the OSA group (Table 1).
Results of Sleep Study
Median total recording time was 472 (405–536) minutes. AHI
ranged from 0.0 to 97.9. Prevalence of OSA was 50.1% based
on diagnostic criteria of AHI ≥15. Patients with OSA exhibited
lower minimum oxygen saturation and excessive daytime
sleepiness than those without OSA. Detailed information is
described in Table 2.
Figure 1. Study ﬂowchart. CPAP indicates continuous positive
airway pressure; OSA, obstructive sleep apnea.
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Procedures and Medications
Procedure and medication information is shown in Table 3.
Most patients received invasive procedures, with coronary
angiography in 97.8%. There were more PCIs (P=0.018)
and stenting (P=0.029) procedures in patients with OSA
than in those without OSA. Prescribed medications on
discharge did not differ between the OSA and non-OSA
groups.
Primary End Point
During a median follow-up of 1 year (0.7–1.7), 81 (10.1%)
patients had MACCE—51 (12.7%) in the OSA group and 30
(7.5%) in the non-OSA group (Table 4). Kaplan–Meier analysis
showed that cumulative incidence of MACCE was signiﬁcantly
higher in the OSA group than in the non-OSA group (log-rank,
P=0.041; Figure 2A). OSA predicted incidence of MACCE in
unadjusted analysis (HR, 1.59; 95% CI, 1.01–2.50; P=0.043;
Table 5). After adjustment for age, sex, body mass index,
hypertension, diabetes mellitus, clinical presentation, PCI
procedure, and minimum arterial oxygen saturation, presence
of OSA was nominally associated with incidence of MACCE,
but this fell short of statistical signiﬁcance (HR, 1.55; 95% CI,
0.94–2.57; P=0.085; Table 5).
In the landmark analysis (Figure 2B and Table 5), there
was no signiﬁcant difference in the incidence of MACCE
between the OSA and non-OSA groups within 1-year follow-up
(adjusted HR, 1.18; 95% CI, 0.67–2.09; P=0.575). In contrast,
during the period after 1 year, patients with OSA had a 3.9-
fold higher risk of MACCE (adjusted HR, 3.87; 95% CI, 1.20–
12.46; P=0.023).
Secondary and Other End Points
Crude numbers of events are listed in Table 4. In general,
most events came from hospitalization for unstable angina or
ischemia-driven revascularization. In Kaplan–Meier analyses,
Table 1. Baseline Patient Characteristics
Variables All (n=804) OSA (n=403) Non-OSA (n=401) P Value
Demographics
Age, y 57.510.2 57.710.2 57.210.2 0.501
Male 664 (82.6) 342 (84.9) 322 (80.3) 0.088
Height, cm 168.57.4 168.77.4 168.37.5 0.477
Weight, kg 76.012.2 78.812.4 73.011.3 <0.001
BMI, kgm2 26.73.6 27.73.5 25.83.4 <0.001
Waist-to-hip ratio 0.98 (0.95–1.02) 0.99 (0.96–1.02) 0.98 (0.94–1.01) <0.001
Neck circumference, cm 40 (38–42) 41 (39–43) 40 (37–41) <0.001
Systolic BP, mm Hg 125 (115–138) 126 (115–140) 125 (116–137) 0.563
Diastolic BP, mm Hg 74 (70–84) 75 (70–85) 73 (68–82) 0.012
Medical history
Diabetes mellitus 248 (30.8) 121 (30.0) 127 (31.7) 0.613
Hypertension 530 (65.9) 275 (68.2) 255 (63.6) 0.165
Hyperlipidemia 210 (26.1) 107 (26.6) 103 (25.7) 0.780
Family history of premature CAD 59 (7.3) 28 (7.0) 31 (7.1) 0.700
Previous stroke 76 (9.5) 41 (10.2) 35 (8.7) 0.484
Previous myocardial infarction 118 (14.7) 61 (15.1) 57 (14.2) 0.712
Previous PCI 141 (17.5) 83 (20.6) 58 (14.5) 0.022
Previous CABG 11 (1.4) 9 (2.2) 2 (0.5) 0.034
Smoking 0.973
No 288 (35.8) 145 (36.0) 143 (35.7)
Current 406 (50.5) 202 (50.1) 204 (50.9)
Previous 110 (13.7) 56 (13.9) 54 (13.5)
Data are presented as meanSD, median (ﬁrst quartile, third quartile), or n (%). BMI indicates body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; PCI, percutaneous coronary intervention; OSA, obstructive sleep apnea.
DOI: 10.1161/JAHA.118.010826 Journal of the American Heart Association 4
OSA and Cardiovascular Outcomes in ACS Fan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on January 28, 2019
no signiﬁcant differences were found in the incidence of
cardiovascular death, MI, and ischemia-driven revasculariza-
tion, except for a higher rate of hospitalization for unstable
angina in the OSA group than in the non-OSA group (log-rank,
P=0.033; Figure 3). Similarly, multivariate analysis showed
higher risk of unstable angina in patients with OSA compared
with those without OSA (HR, 2.10; 95% CI, 1.09–4.05;
P=0.027; Table 5). Moreover, incidence of all events was
signiﬁcantly higher in the OSA group than in the non-OSA
group in the landmark analysis after 1 year (adjusted HR,
3.67; 95% CI, 1.13–11.95; P=0.031; Table 5).
Discussion
The prospective cohort study showed that OSA was
nominally associated with increased incidence of MACCE
in patients with ACS. However, multivariable analysis
showed that there was no independent correlation between
Table 2. Results of Sleep Study
Variables All (n=804) OSA (n=403) Non-OSA (n=401) P Value
AHI, eventsh1 15.0 (7.4–31.2) 31.2 (21.8–43.8) 7.4 (3.8–10.6) <0.001
ODI, eventsh1 14.4 (7.4–29.5) 29.5 (21.2–43.3) 7.8 (4.2–11.2) <0.001
Minimum SaO2, % 85 (79–88) 82 (75–86) 87 (84–90) <0.001
Mean SaO2, % 94 (93–95) 93 (92–94) 95 (94–96) <0.001
Time with SaO2 <90%, % 1.2 (0.1–7.2) 5.2 (1.2–13.4) 0.2 (0.0–1.4) <0.001
Epworth sleepiness scale 8.35.0 8.94.9 7.75.1 0.029
Data are presented as meanSD or median (ﬁrst quartile, third quartile). AHI indicates apnea-hypopnea index; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; SaO2, arterial
oxygen saturation.
Table 3. Clinical Presentations and Management
Variables All (n=804) OSA (n=403) Non-OSA (n=401) P Value
ACS category 0.214
Unstable angina 347 (43.2) 179 (44.4) 168 (41.9)
NSTEMI 203 (25.2) 91 (22.6) 112 (27.9)
STEMI 254 (31.6) 133 (33.0) 121 (30.2)
LVEF, % 60 (55–65) 60 (55–65) 60 (55–65) 0.277
Coronary angiography 786 (97.8) 397 (98.5) 389 (97.0) 0.150
PCI 490 (60.9) 262 (65.0) 228 (56.9) 0.018
Stenting 432 (53.7) 232 (57.6) 200 (49.9) 0.029
Stents implanted, n 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.497
CABG 80 (10.0) 37 (9.2) 43 (10.7) 0.465
Medications on discharge
Aspirin 754 (93.8) 381 (94.5) 373 (93.0) 0.371
Thienopyridine 720 (89.6) 369 (91.6) 351 (87.5) 0.062
b-blockers 611 (76.0) 313 (77.7) 298 (74.3) 0.266
ACEIs/ARBs 564 (70.1) 291 (72.2) 273 (68.1) 0.201
Statins 762 (94.8) 385 (95.5) 377 (94.0) 0.333
Aldosterone receptor antagonist 47 (5.8) 28 (6.9) 19 (4.7) 0.182
Diuretics 56 (7.0) 34 (8.4) 22 (5.5) 0.100
Calcium antagonists 124 (15.4) 65 (16.1) 59 (14.7) 0.578
Data are presented as median (ﬁrst quartile, third quartile) or n (%). ACEIs indicates angiotensin-converting enzymes inhibitors; ACS, acute coronary syndrome; ARBs, angiotensin receptor
blockers; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; OSA, obstructive sleep apnea; PCI,
percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction.
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OSA and 1-year MACCE after ACS. The difference between
the 2 groups was driven by an increase of hospitalizations
for unstable angina in the OSA group. In the landmark
analysis, patients with OSA had 3.9 times the risk of
incurring a MACCE after 1 year, but no increased risk was
evident within 1 year, suggesting that the adverse effect of
OSA might become more pronounced with an increasing
duration of follow-up.
Table 4. Crude Number of Events During Follow-up
Variables All (n=804) OSA (n=403) Non-OSA (n=401)
MACCE 81 (10.1) 51 (12.7) 30 (7.5)
Cardiovascular death 11 (1.4) 5 (1.2) 6 (1.5)
Myocardial infarction 11 (1.4) 4 (1.0) 7 (1.7)
Stroke 9 (1.1) 6 (1.5) 3 (0.7)
Ischemic 6 (1.0) 4 (1.0) 2 (0.5)
Hemorrhagic 3 (0.4) 2 (0.5) 1 (0.2)
Hospitalization for unstable angina 49 (6.1) 33 (8.2) 16 (4.0)
Hospitalization for heart failure 6 (0.7) 3 (0.7) 3 (0.7)
Ischemia-driven revascularization 27 (3.4) 17 (4.2) 10 (2.5)
All-cause mortality 11 (1.4) 5 (1.2) 6 (1.5)
All repeat revascularization 48 (6.0) 28 (6.9) 20 (5.0)
Target vessel revascularization 14 (1.7) 9 (2.2) 5 (1.2)
Non-target-vessel revascularization 40 (5.0) 23 (5.7) 17 (4.2)
PCI 42 (5.2) 26 (6.5) 16 (4.0)
CABG 6 (0.7) 2 (0.5) 4 (1.0)
Composite of all events 100 (12.4) 61 (15.1) 39 (9.7)
Data are presented as n (%). CABG indicates coronary artery bypass grafting; MACCE major adverse cardiovascular and cerebrovascular event; OSA, obstructive sleep apnea; PCI,
percutaneous coronary intervention.
Figure 2. Kaplan–Meier curves for the overall and landmark analysis of MACCE. Cumulative incidences of
MACCE are shown in the overall (A) and landmark (B) analysis, stratiﬁed on the basis of a cut-off point at 1 year
after sleep study (vertical dashed line). HRs for OSA vs non-OSA groups were calculated separately for events
that occurred within 1 year and those that occurred between 1 year and the end of follow-up. HR indicates
hazard ratio; MACCE, major adverse cardiovascular and cerebrovascular event; OSA, obstructive sleep apnea.
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Despite therapeutic advances, including greater use of
reperfusion therapy and modern antithrombotic therapy, mor-
tality following ACS remains substantial. In the national
registries of the European Society of Cardiology countries, in-
hospital mortality of ST-segment elevation myocardial infarc-
tion patients varies between 4% and 12%,18 and reported 1-year
mortality among ST-segment elevation myocardial infarction
patients in angiography registries is 10%.19,20 Consequently,
it is important to identify potential factors that might contribute
to worsening of clinical outcomes in patients with ACS.
OSA-mediated intermittent hypoxia, triggered by repetitive
bursts of apneas and hypopneas, is a major contributing factor
to cardiovascular impairment.21 Recurrent cycles of hypox-
emia with reoxygenation promote oxidative stress, sympa-
thetic activation, and inﬂammatory responses, resulting in
endothelial dysfunction21 and reduction of repair capacity,22
which exacerbate progression of atherosclerosis and plaque
instability. Based on intravascular ultrasound, patients with
OSA had a larger total atheroma volume than those without
OSA.4 In a large ACS cohort study, OSA was associated with an
increased number of diseased vessels.23 In our study, there
were more PCI procedures in OSA patients. In addition,
patients with OSA showed increased platelet activation and
aggregation24 and reduced ﬁbrinolytic capacity,25 all of which
predispose to thrombotic events. Several observational stud-
ies and meta-analysis have shown a higher risk of long-term
cardiovascular events in patients with OSA,9–12,26 but most
studies were done in the era before new-generation drug-
eluting stents and potent antiplatelet therapy. To the best of
our knowledge, the present study is 1 of the largest cohorts to
examine impact of OSA on cardiovascular outcomes of ACS
patients in the contemporary era. Our results demonstrate that
patients with OSA might have a greater risk of MACCE after
ACS onset, even if most patients have received revasculariza-
tion and optimal medical therapy.
Speciﬁcally, our results indicate that increased risk in OSA
patients was obvious only after 1 year. This may be explained
by the fact that patients are under guideline-based therapy
Table 5. Overall and Landmark Analysis for the Adverse Events in Patients With OSA Versus Those Without OSA
Variables Unadjusted HR (95% CI) P Value Adjusted HR (95% CI)* P Value
Overall analysis
MACCE 1.59 (1.01–2.50) 0.043 1.55 (0.94–2.57) 0.085
Cardiovascular death† 0.80 (0.25–2.63) 0.716  
Myocardial infarction† 0.54 (0.16–1.85) 0.327  
Stroke† 1.93 (0.48–7.71) 0.353  
Ischemia-driven revascularization 1.57 (0.72–3.42) 0.261 1.52 (0.65–3.56) 0.334
Hospitalization for unstable angina 1.89 (1.04–3.44) 0.036 2.10 (1.09–4.05) 0.027
Hospitalization for heart failure† 0.97 (0.20–4.81) 0.972  
All repeat revascularization 1.32 (0.75–2.35) 0.340 1.51 (0.81–2.83) 0.195
Composite of all events 1.48 (0.99–2.21) 0.057 1.54 (0.98–2.40) 0.059
Landmark analysis (≤1 y)
MACCE 1.27 (0.76–2.12) 0.353 1.18 (0.67–2.09) 0.575
Hospitalization for unstable angina 1.62 (0.79–3.31) 0.187 1.84 (0.84–4.03) 0.130
Ischemic-driven revascularization 1.21 (0.48–3.07) 0.688 1.27 (0.46–3.50) 0.646
All repeat revascularization 1.14 (0.61–2.14) 0.682 1.41 (0.71–2.82) 0.328
Composite of all events 1.26 (0.81–1.96) 0.310 1.28 (0.78–2.09) 0.322
Landmark analysis (>1 y)
MACCE 3.55 (1.20–10.56) 0.023 3.87 (1.20–12.46) 0.023
Hospitalization for unstable angina 2.68 (0.87–8.21) 0.085 2.82 (0.84–9.51) 0.095
Ischemic-driven revascularization 2.92 (0.61–14.04) 0.182 2.46 (0.46–13.26) 0.295
All repeat revascularization 2.85 (0.59–13.71) 0.192 2.54 (0.47–13.73) 0.278
Composite of all events 3.30 (1.10–9.86) 0.033 3.67 (1.13–11.95) 0.031
HR indicates hazard ratio; MACCE, major adverse cardiovascular and cerebrovascular event; OSA, obstructive sleep apnea; PCI, percutaneous coronary intervention.
*Model adjusted for age, sex, body mass index, hypertension, and diabetes mellitus, clinical presentation (acute myocardial infarction vs unstable angina), PCI procedure, and minimum
SaO2.
†
Multivariate Cox regression and landmark analysis was not done because of too few events.
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after ACS presentation (especially within 1 year), including
intensive antiplatelet therapy and control of blood pressure,
dyslipidemia, and glucose, which are also the intermediate
mechanisms implicated in OSA.2 Furthermore, some reports
suggested that OSA may play a cardioprotective role in the
acute phase of MI.27 In contrast, OSA may have a chronic
deleterious effect in the long run, which was veriﬁed in our
study showing increased events after 1 year, consistent with
previous studies with long-term follow-up.9,28
According to recent randomized trials and meta-analysis,
treatment of OSA with CPAP may not confer signiﬁcant
cardiovascular beneﬁt among patients with established cardio-
vascular disease.29–31 In a trial that enrolled 224 patients with
OSA and coronary artery disease who had undergone revascu-
larization, no difference was found in a composite end point of
repeat revascularization, MI, stroke, or cardiovascular death in
patients with CPAP versus those without CPAP therapy. The
Kaplan–Meier curve suggests that CPAP may be harmful in the
ﬁrst 12 months following randomization, and modest beneﬁts
may emerge in the long-term follow-up.29 Speciﬁcally, despite
recommendations for treatment, the vast majority of patients in
our study did not proceed to consideration for CPAP therapy
Figure 3. Kaplan–Meier curves for the individual cardiovascular events. Shown are the cumulative
incidences of cardiovascular death (A), myocardial infarction (B), hospitalization for unstable angina (C), and
ischemia-driven revascularization (D). OSA indicates obstructive sleep apnea.
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because of unawareness of signiﬁcance of OSA, a ﬁnding also
observed in another study of OSA patients afterMI.32 In this case,
treatment effects of CPAP for secondary prevention of coronary
artery disease still need to be evaluated, especially in a high-risk
group (ACS,MI, etc). Also, the appropriate duration of intervention
warrants further investigation, given that any randomized trial of
CPAP or other therapy for 1 year or less will be unlikely to
demonstrate signiﬁcant beneﬁt of therapy, given the absence of
signiﬁcant risk associated with OSA within the ﬁrst year of ACS.
Study Limitations
First, OSA was detected by cardiorespiratory monitoring rather
than complete polysomnography. Although the portable
devices may underestimate AHI as a consequence of overes-
timating actual sleeping time, it is a simple and safe way to
identify OSA in this high-risk patient population. Second,
whereas it is possible that severity of OSA may change in the
weeks after ACS,33 this is true for OSA evaluation in the setting
of any acute disease, including heart failure. Also, patients in our
study received a sleep study after clinical stabilization, thus
minimizing the potential bias. Third, follow-up duration was
relatively shorter. Also, a previous study indicated that noctur-
nal hypoxemia in OSA is a predictor of poor outcome after MI in
the long run.32 Therefore, longer follow-up of this cohort is
needed. Finally, this study is a single-center study that recruited
primarily East-Asian patients. Studies pertaining to other
ethnicities are needed.
Conclusions
In this prospective cohort study, OSA was not independently
associated with a higher incidence of MACCE in patients with
ACS. However, an increased risk associated with OSA was
observed during the period after 1 year. Efﬁcacy of CPAP
therapy for secondary prevention and timing of intervention
after ACS need further evaluation.
Acknowledgments
The authors thank Dr Qiuju Deng (Department of Epidemiology, Beijing
Institute of Heart Lung and Blood Vessel Diseases, Beijing Anzhen
Hospital, Capital Medical University, Beijing, China) for her help in
statistics and also thank Drs Wen Hao, Guanqi Zhao, Shenghui Zhou,
Aobo Li, Ruifeng Guo, Han Shi, and Zexuan Li (Emergency & Critical
Care Center, Beijing Anzhen Hospital, Capital Medical University,
Beijing, China) for collecting the data involved in this study.
Sources of Funding
This study was supported by grants from the International
Science & Technology Cooperation Program of China
(2015DFA30160), National Natural Science Foundation of
China (81600209, 81870322), BeijingMunicipal Administration
of Hospitals Clinical Medicine Development of Special Funding
Support (ZYLX201710), Beijing Municipal Administration of
Hospitals’ Ascent Plan (DFL20180601), Beijing Municipal
Science and Technology Commission (Z181100001718060),
Beijing Municipal Administration of Hospitals’ Youth Program
(QML20160605), and Beijing Municipal Administration of
Hospitals Incubating Program (PX2016048).
Disclosures
Dr Somers served as a consultant for Phillips Respironics,
ResMed, Respicardia, GlaxoSmithKline, Itamar, U-Health, and
Bayer. The remaining authors have no disclosures to report.
References
1. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S,
Malhotra A, Martinez-Garcia MA, Mehra R, Pack AI, Polotsky VY, Redline S,
Somers VK. Sleep apnea: types, mechanisms, and clinical cardiovascular
consequences. J Am Coll Cardiol. 2017;69:841–858.
2. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S; INCOSACT Initiative
(International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep
apnea and cardiovascular disease: lessons from recent trials and need for
team science. Circulation. 2017;136:1840–1850.
3. Weinreich G, Wessendorf TE, Erdmann T, Moebus S, Dragano N, Lehmann N,
Stang A, Roggenbuck U, Bauer M, Jockel KH, Erbel R, Teschler H, Mohlenkamp
S. Association of obstructive sleep apnoea with subclinical coronary
atherosclerosis. Atherosclerosis. 2013;231:191–197.
4. Tan A, Hau W, Ho HH, Ghaem Maralani H, Loo G, Khoo SM, Tai BC, Richards
AM, Ong P, Lee CH. OSA and coronary plaque characteristics. Chest.
2014;145:322–330.
5. Arzt M, Hetzenecker A, Steiner S, Buchner S. Sleep-disordered breathing and
coronary artery disease. Can J Cardiol. 2015;31:909–917.
6. Martinez-Garcia MA, Campos-Rodriguez F, Soler-Cataluna JJ, Catalan-Serra P,
Roman-Sanchez P, Montserrat JM. Increased incidence of nonfatal cardiovas-
cular events in stroke patients with sleep apnoea: effect of CPAP treatment.
Eur Respir J. 2012;39:906–912.
7. Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG,
Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC,
Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C,
Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS,
Valgimigli M, Kastrati A, Chieffo A, Mehran R. Impact of clinical presentation
(stable angina pectoris vs unstable angina pectoris or non-ST-elevation
myocardial infarction vs ST-elevation myocardial infarction) on long-term
outcomes in women undergoing percutaneous coronary intervention with
drug-eluting stents. Am J Cardiol. 2015;116:845–852.
8. Koo CY, de la Torre AS, Loo G, Torre MS, Zhang J, Duran-Cantolla J, Li R, Mayos
M, Sethi R, Abad J, Furlan SF, Coloma R, Hein T, Ho HH, Jim MH, Ong TH, Tai
BC, Turino C, Drager LF, Lee CH, Barbe F. Effects of ethnicity on the
prevalence of obstructive sleep apnoea in patients with acute coronary
syndrome: a pooled analysis of the ISAACC Trial and Sleep and Stent Study.
Heart Lung Circ. 2017;26:486–494.
9. Mazaki T, Kasai T, Yokoi H, Kuramitsu S, Yamaji K, Morinaga T, Masuda H,
Shirai S, Ando K. Impact of sleep-disordered breathing on long-term outcomes
in patients with acute coronary syndrome who have undergone primary
percutaneous coronary intervention. J Am Heart Assoc. 2016;5:e003270. DOI:
10.1161/JAHA.116.003270.
10. Meng S, Fang L, Wang CQ, Wang LS, Chen MT, Huang XH. Impact of
obstructive sleep apnoea on clinical characteristics and outcomes in patients
with acute coronary syndrome following percutaneous coronary intervention. J
Int Med Res. 2009;37:1343–1353.
11. Yumino D, Tsurumi Y, Takagi A, Suzuki K, Kasanuki H. Impact of obstructive
sleep apnea on clinical and angiographic outcomes following percutaneous
coronary intervention in patients with acute coronary syndrome. Am J Cardiol.
2007;99:26–30.
12. Lee CH, Sethi R, Li R, Ho HH, Hein T, Jim MH, Loo G, Koo CY, Gao XF, Chandra
S, Yang XX, Furlan SF, Ge Z, Mundhekar A, Zhang WW, Uchoa CH, Kharwar RB,
DOI: 10.1161/JAHA.118.010826 Journal of the American Heart Association 9
OSA and Cardiovascular Outcomes in ACS Fan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on January 28, 2019
Chan PF, Chen SL, Chan MY, Richards AM, Tan HC, Ong TH, Roldan G, Tai BC,
Drager LF, Zhang JJ. Obstructive sleep apnea and cardiovascular events after
percutaneous coronary intervention. Circulation. 2016;133:2008–2017.
13. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,
Lenzen MJ, Prescott E, Rofﬁ M, Valgimigli M, Varenhorst C, Vranckx P,
Widimsky P. 2017 ESC guidelines for the management of acute myocardial
infarction in patients presenting with ST-segment elevation: the Task Force for
the management of acute myocardial infarction in patients presenting with ST-
segment elevation of the European Society of Cardiology (ESC). Eur Heart J.
2018;39:119–177.
14. Rofﬁ M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K,
Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S,
Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C,
Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D,
Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS,
Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis
Zamorano J. 2015 ESC guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment elevation:
Task Force for the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J. 2016;37:267–315.
15. Antic NA, Heeley E, Anderson CS, Luo Y, Wang J, Neal B, Grunstein R, Barbe F,
Lorenzi-Filho G, Huang S, Redline S, Zhong N, McEvoy RD. The Sleep Apnea
cardioVascular Endpoints (SAVE) Trial: rationale, ethics, design, and progress.
Sleep. 2015;38:1247–1257.
16. Gantner D, Ge JY, Li LH, Antic N, Windler S, Wong K, Heeley E, Huang SG, Cui P,
Anderson C, Wang JG, McEvoy D. Diagnostic accuracy of a questionnaire and
simple home monitoring device in detecting obstructive sleep apnoea in a
Chinese population at high cardiovascular risk. Respirology. 2010;15:952–960.
17. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC,
Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen
SE, Smith EE, Targum SL. 2014 ACC/AHA key data elements and deﬁnitions
for cardiovascular endpoint events in clinical trials: a report of the American
College of Cardiology/American Heart Association Task Force on Clinical Data
Standards (Writing Committee to Develop Cardiovascular Endpoints Data
Standards). J Am Coll Cardiol. 2015;66:403–469.
18. Kristensen SD, Laut KG, Fajadet J, Kaifoszova Z, Kala P, Di Mario C, Wijns W,
Clemmensen P, Agladze V, Antoniades L, Alhabib KF, De Boer MJ, Claeys MJ,
Deleanu D, Dudek D, Erglis A, Gilard M, Goktekin O, Guagliumi G, Gudnason T,
Hansen KW, Huber K, James S, Janota T, Jennings S, Kajander O, Kanakakis J,
Karamﬁloff KK, Kedev S, Kornowski R, Ludman PF, Merkely B, Milicic D,
Najafov R, Nicolini FA, Noc M, Ostojic M, Pereira H, Radovanovic D, Sabate M,
Sobhy M, Sokolov M, Studencan M, Terzic I, Wahler S, Widimsky P; European
Association for Percutaneous Cardiovascular Interventions. Reperfusion
therapy for ST elevation acute myocardial infarction 2010/2011: current
status in 37 ESC countries. Eur Heart J. 2014;35:1957–1970.
19. Pedersen F, Butrymovich V, Kelbaek H, Wachtell K, Helqvist S, Kastrup J,
Holmvang L, Clemmensen P, Engstrom T, Grande P, Saunamaki K, Jorgensen E.
Short- and long-term cause of death in patients treated with primary PCI for
STEMI. J Am Coll Cardiol. 2014;64:2101–2108.
20. Fokkema ML, James SK, Albertsson P, Akerblom A, Calais F, Eriksson P, Jensen
J, Nilsson T, de Smet BJ, Sjogren I, Thorvinger B, Lagerqvist B. Population
trends in percutaneous coronary intervention: 20-year results from the SCAAR
(Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol.
2013;61:1222–1230.
21. Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implica-
tions for comorbidities. Chest. 2015;147:266–274.
22. Jelic S, Padeletti M, Kawut SM, Higgins C, Canﬁeld SM, Onat D, Colombo PC,
Basner RC, Factor P, LeJemtel TH. Inﬂammation, oxidative stress, and repair
capacity of the vascular endothelium in obstructive sleep apnea. Circulation.
2008;117:2270–2278.
23. Barbe F, Sanchez-de-la-Torre A, Abad J, Duran-Cantolla J, Mediano O, Amilibia
J, Masdeu MJ, Flores M, Barcelo A, de la Pena M, Aldoma A, Worner F, Valls J,
Castella G, Sanchez-de-la-Torre M; Spanish Sleep Network. Effect of obstruc-
tive sleep apnoea on severity and short-term prognosis of acute coronary
syndrome. Eur Respir J. 2015;45:419–427.
24. Bokinsky G, Miller M, Ault K, Husband P, Mitchell J. Spontaneous platelet
activation and aggregation during obstructive sleep apnea and its response to
therapy with nasal continuous positive airway pressure. A preliminary
investigation. Chest. 1995;108:625–630.
25. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K. Platelet function
and ﬁbrinolytic activity in hypertensive and normotensive sleep apnea
patients. Sleep. 1995;18:188–194.
26. Wang X, Fan JY, Zhang Y, Nie SP, Wei YX. Association of obstructive sleep
apnea with cardiovascular outcomes after percutaneous coronary interven-
tion: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:
e0621.
27. Mohananey D, Villablanca PA, Gupta T, Agrawal S, Faulx M, Menon V, Kapadia
SR, Grifﬁn BP, Ellis SG, Desai MY. Recognized obstructive sleep apnea is
associated with improved in-hospital outcomes after ST elevation myocardial
infarction. J Am Heart Assoc. 2017;6:e006133. DOI: 10.1161/JAHA.117.
006133.
28. Uchoa CHG, Pedrosa RP, Javaheri S, Geovanini GR, Carvalho MMB, Torquatro
ACS, Leite A, Gonzaga CC, Bertolami A, Amodeo C, Petisco A, Barbosa JEM,
Macedo TA, Bortolotto LA, Oliveira MT Jr, Lorenzi-Filho G, Drager LF. OSA and
prognosis after acute cardiogenic pulmonary edema: the OSA-CARE study.
Chest. 2017;152:1230–1238.
29. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunstrom E.
Effect of positive airway pressure on cardiovascular outcomes in coronary
artery disease patients with nonsleepy obstructive sleep apnea. The
RICCADSA randomized controlled trial. Am J Respir Crit Care Med.
2016;194:613–620.
30. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R,
Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li
Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP,
Grunstein RR, Zhong N, Anderson CS; SAVE Investigators and Coordinators.
CPAP for prevention of cardiovascular events in obstructive sleep apnea. N
Engl J Med. 2016;375:919–931.
31. Wang X, Zhang Y, Dong Z, Fan J, Nie S, Wei Y. Effect of continuous positive
airway pressure on long-term cardiovascular outcomes in patients with
coronary artery disease and obstructive sleep apnea: a systematic review and
meta-analysis. Respir Res. 2018;19:61.
32. Xie J, Sert Kuniyoshi FH, Covassin N, Singh P, Gami AS, Wang S, Chahal CA,
Wei Y, Somers VK. Nocturnal hypoxemia due to obstructive sleep apnea is an
independent predictor of poor prognosis after myocardial infarction. J Am
Heart Assoc. 2016;5:e003162. DOI: 10.1161/JAHA.115.003162.
33. Low TT, Hong WZ, Tai BC, Hein T, Khoo SM, Tan AY, Chan MY, Richards M, Lee
CH. The inﬂuence of timing of polysomnography on diagnosis of obstructive
sleep apnea in patients presenting with acute myocardial infarction and stable
coronary artery disease. Sleep Med. 2013;14:985–990.
DOI: 10.1161/JAHA.118.010826 Journal of the American Heart Association 10
OSA and Cardiovascular Outcomes in ACS Fan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on January 28, 2019
